Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher BioSpacePartner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner's National Priority Voucher to accelerate drug review.OncologyRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) BioSpace Partner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner’s National Priority Voucher to accelerate drug review. Oncology Read full story Post navigation Previous: Deal finally unlocks NHS access to ITF’s Duchenne drugNext: Novo Nordisk microRNA drug fluffs its lines in heart failure Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026